Efficacy of infliximab biosimilars in patients with Crohn's disease

Lancet. 2017 Dec 2;390(10111):2435. doi: 10.1016/S0140-6736(17)32459-5. Epub 2017 Dec 1.

Author

Pierre Michetti¹

Affiliation

¹ Gastroenterology La Source-Beaulieu, 1004 Lausanne, Switzerland; Division of Gastroenterology, Lausanne University Hospital, Lausanne, Switzerland. Electronic address: pmichetti@gesb.ch.

PMID: 29208302
DOI: 10.1016/S0140-6736(17)32459-5

No abstract available

Publication types

Letter
Comment

MeSH terms

Antibodies, Monoclonal
Biosimilar Pharmaceuticals
Crohn Disease*
Gastrointestinal Agents
Humans
Immunosuppressive Agents
Infliximab*
Treatment Outcome

Substances

Antibodies, Monoclonal
Biosimilar Pharmaceuticals
Gastrointestinal Agents
Immunosuppressive Agents
Infliximab